Global /Taiwan /Healthcare /Drug Manufacturers - General /4120
chevron_leftBack
Orient EuroPharma Co., Ltd. logo

Orient EuroPharma Co., Ltd.

4120
TPEX: 4120 Delayed
48.00TWD 3.9%
1.53 USD
As of 5 June 2026, Orient EuroPharma Co., Ltd. has a market cap of $127.4M USD, ranking #23921 globally and #1234 in Taiwan. It ranks #2151 in the Healthcare sector, and #781 in the Drug Manufacturers - General industry.
Global Rank
23921
Country Rank
1234
Sector Rank
2151
Industry Rank
781
Key Stats
Market Cap
$127.4MUSD
4.01B TWD
Enterprise Value
$198.64MUSD
6.25B TWD
Revenue (TTM)
$146.08MUSD
4.6B TWD
EBITDA (TTM)
-$4.93MUSD
-155.08M TWD
Net Income (TTM)
-$18.04MUSD
-567.39M TWD
EBITDA Margin
-3.4%
Profit Margin
-12%
PS Ratio
0.9
PB Ratio
0.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mon-Lin Tsai open_in_new
Employees
339
Founded
1982
Website
oepgroup.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
3.9% 2.1% 4% 7% 2% 4.3%

News

Loading...

Markets

Exchange Ticker Price
Taipei Exchange
MIC: ROCO
PRIMARY
4120
友華生技醫藥股份有限公司
ISIN: TW0004120001
Shares Out.:
86.747M1 Shares Float: 40.908M2
TV:
SA:
YF:
GF:
BA:
MS:
48.00 TWD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Orient EuroPharma Co., Ltd.

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient EuroPharma Co., Ltd. was incorporated in 1982 and is based in Taipei, Taiwan.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)
Name
Market Cap diff.
PE
$7.8B
245.34B TWD
6K%
48.6
$1.84B
57.95B TWD
1K%
12.2
$925.55M
29.11B TWD
626%
3.4
$809.3M
25.46B TWD
535%
-
$789.12M
24.82B TWD
519%
-
$584.14M
18.38B TWD
358%
11.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
598K%
38.1
JNJ
$547.28B
429K%
26.4
ABBV
$360.63B
283K%
97.4
$323.4B
256.25B CHF
254K%
19.9
AZN
$289.25B
215.59B GBP
227K%
27.6
NOVN
$276.26B
218.9B CHF
217K%
20.5
chevron_leftBack